Efficacy of trimetazidine MB in composite treatment of moderate heart failure and asymptomatic left ventricle dysfunction in patients with acute myocardial infarction
Background. Positive effect of trimetazidine in patients with symptomatic CHF or asymptomatic LV dysfunction on standard therapy was previously demonstrated. However, there is no data on efficacy of trimetazidine MB in patients with MI and symptomatic CHF or asymptomatic LV dysfunction. Objective. To investigate and substantiate the possibility of Trimetazidine MR usage in the treatment of moderate HF and asymptomatic left ventricular dysfunction in patients with MI. Materials and methods. In this open randomized study 120 patients with MI and moderate CH (I-II FC) or asymptomatic LV dysfunction took part. Efficacy of standard therapy and its combination with trimetazidine MB (preductal MB) was evaluated. During 6-months follow-up dynamics of clinical condition and indicators of left ventricular ejection fraction were analysed. Results. In patients treated with trimetazidine MB less relapses or recurrent MI occurred as well as recurrent hospitalizations (including decompensated CHF). Significant positive dynamics of clinical condition, LVEF, significant decrease of CHF FC were observed. Thus, trimetazidine MB can be recommended as a part of complex therapy of patients with MI and moderate chronic heart failure or asymptomatic LV dysfunction.